Added to YB: 2025-02-20
Pitch date: 2025-01-04
AVDL [bullish]
Avadel Pharmaceuticals plc
+95.13%
current return
Author Info
No bio for this author
Company Info
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.
Market Cap
$2.1B
Pitch Price
$11.09
Price Target
30.00 (+39%)
Dividend
N/A
EV/EBITDA
568.72
P/E
-7.5K
EV/Sales
8.33
Sector
Pharmaceuticals
Category
value
Avadel Pharmaceuticals plc - $AVDL
AVDL: Undervalued biotech with successful Narcolepsy drug LUMRYZ. Q4 2023 likely profitable. $20+ value today, $25-30 in 2 years. Misunderstood Q3 results & CCO departure caused dip. 50%+ market share potential, $800-900M peak revenue. Legal risks mostly resolved. 80c EPS 2025, $1.99 2026, $2.64 2027. Upside from IH approval, low-sodium version, potential acquisition.
Read full article (12 min)